(1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: further optimisation as highly potent and selective MSK-1-inhibitors |
| |
| Authors: | Bamford Mark J Bailey Nicholas Davies Susannah Dean David K Francis Leann Panchal Terence A Parr Christopher A Sehmi Sanjeet Steadman Jon G Takle Andrew K Townsend James T Wilson David M |
| |
| Affiliation: | GlaxoSmithKline Pharmaceuticals, Neurology & GI Centre of Excellence for Drug Discovery, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW, UK. Mark_J_Bamford@GSK.com |
| |
| Abstract: | The novel imidazo[4,5-c]pyridine 1,2,5-oxadiazol-3-yl template affords an excellent start point for identification of inhibitors of a number of protein kinases. Here we report on its optimisation for mitogen and stress-activated protein kinase-1 (MSK-1) inhibitory activity, and selectivity over other kinases. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect PubMed 等数据库收录！ |
|
